High Expression of Dihydropyrimidine Dehydrogenase in Lung Adenocarcinoma is Associated With Mutations in Epidermal Growth Factor Receptor: Implications for the Treatment of Non–Small-Cell Lung Cancer Using 5-Fluorouracil

Background It has been shown that 5-fluorouracil (5-FU) sensitivity in patients with non–small-cell lung cancer (NSCLC) is associated with epidermal growth factor receptor (EGFR) mutation status. However, the relationship between dihydropyrimidine dehydrogenase (DPD), a 5-FU degrading enzyme, and EGFR mutation status is unknown. Here, we focus on clinicopathologic factors and in vitro correlations between DPD expression and EGFR mutation status. Patients and Methods EGFR mutations and messenger RNA (mRNA) levels of DPD and thymidylate synthase (TS) were analyzed in 47 resected NSCLC tumors by laser-capture microdissection. In addition, relationships between EGFR mutation status and the immunohistochemical expression of DPD and TS in 49 patients with primary NSCLC who were treated with a 5-FU derivative of S-1 postoperatively were examined. Correlations among clinicopathologic factors were evaluated. The effect of epidermal growth factor on DPD expression was also investigated in vitro in various cell lines. Results Adenocarcinoma in situ showed significantly higher DPD mRNA levels and more EGFR mutation frequency than other histological types (P < .05). DPD immunopositive cases were more frequently observed in adenocarcinoma, in females, and in nonsmokers. DPD immunopositive cases were correlated with EGFR mutation status (P < .003). The prognoses of wild-type EGFR and mutated EGFR populations were similarly favorable with postoperative S-1 treatment, which overcomes the problem of 5-FU degradation in mutated EGFR. In vitro, EGFR-mutated cell lines showed high DPD mRNA and protein expression. Conclusion High DPD expression was shown to be correlated with EGFR mutation in adenocarcinoma cells and tissues. Clinicians should take this finding into consideration when using 5-FU to treat patients with NSCLC.;開始ページ : 136;終了ページ : 144;元資料の権利情報 : © 2014 Elsevier Inc.;元資料の権利情報 : NOTICE: this is the author's version of a work that was accepted for publication in Clinical Lung Cancer. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Clinical Lung Cancer, 15, 2, (2014)

「国立国会図書館デジタルコレクション(雑誌)」より

この本の情報

書名 High Expression of Dihydropyrimidine Dehydrogenase in Lung Adenocarcinoma is Associated With Mutations in Epidermal Growth Factor Receptor: Implications for the Treatment of Non–Small-Cell Lung Cancer Using 5-Fluorouracil
著作者等 Cancer Information Group
持永 浩史
書名別名 肺腺癌におけるDPD高発現はEGFR遺伝子変異と関連する:5-FU系抗癌剤を用いた非小細胞肺癌治療への影響について
出版元 Elsevier
ページ数 v.
大きさ 28 cm
ISSN 15257304
NCID AA11973261
AA12794100
※クリックでCiNii Booksを表示
言語 英語
出版国 アメリカ合衆国
この本を: 
このエントリーをはてなブックマークに追加

Yahoo!ブックマークに登録
この記事をクリップ!
Clip to Evernote
このページを印刷

外部サイトで検索

この本と繋がる本を検索

ウィキペディアから連想